Updates are available Correction dated 2025-11-10

Article History

Received: 21 October 2024

Revised: 17 February 2025

Accepted: 17 February 2025

First Online: 12 March 2025

Change Date: 31 October 2025

Change Type: Update

Change Details: The original online version of this article was revised: In the original article co-authors Gábor B. Brenner, András Makkos, Tamás G. Gergely and Nabil V. Sayour were missing from the author group due to an administrative error on the authors’ part.

Change Date: 10 November 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00395-025-01142-9

Declarations

:

: TK is Chief Medical Officer and Founder of Camoxis Ltd. TK and HAP are in part funded by the British Heart Foundation. P.F. is the founder and CEO, and ZG is involved in the management of Pharmahungary Group, a group of R&D companies. DJH has received: consultant fees from Faraday Pharmaceuticals Inc. and Boehringer Ingelheim International GmbH; honoraria from Servier; and research funding from Astra Zeneca, Merck Sharp & Dohme Corp and Novonordisk. All other authors declare no competing interests. In case of industrial interest, Pharmahungary Group will organize multicenter studies involving the selected and validated sites of the current COST action (IG16225) according to the COST action final report.